A phase I dose-escalation study of the polyamine analog PG-11047 in patients with advanced solid tumors

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2020-05-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-020-04082-4PMID 32447421PMCID PMC7337042
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Myc, Oncogenic Protein Translation, and the Role of Polyamines

  2018cited by this paper
• Polyamine metabolism and cancer: treatments, challenges and opportunities

  2018cited by this paper
• Biochemical evaluation of the anticancer potential of the polyamine-based nanocarrier Nano11047

  2017cited by this paper
• Self‐immolative nanoparticles for simultaneous delivery of microRNA and targeting of polyamine metabolism in combination cancer therapy

  2017cited by this paper
• Targeting polyamine metabolism for cancer therapy and prevention.

  2016cited by this paper
• DFMO: targeted risk reduction therapy for colorectal neoplasia.

  2011cited by this paper
• Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program

  2011cited by this paper
• Reduction of the putative CD44+CD24− breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047

  2010cited by this paper
• The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer

  2009cited by this paper
• A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047

  2009cited by this paper
• Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047.

  2009cited by this paper
• Nuclear localization of human spermine oxidase isoforms – possible implications in drug response and disease etiology

  2008cited by this paper
• Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial

  2008cited by this paper
• In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells

  2008cited by this paper
• Antizyme and antizyme inhibitor activities influence cellular responses to polyamine analogs

  2007cited by this paper
• Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases

  2007cited by this paper
• Differential polyamine analogue effects in four human breast cancer cell lines.

  2006cited by this paper
• Spermine Oxidase SMO(PAOh1), Not N1-Acetylpolyamine Oxidase PAO, Is the Primary Source of Cytotoxic H2O2 in Polyamine Analogue-treated Human Breast Cancer Cell Lines*

  2005cited by this paper
• Unusual central nervous system toxicity in a phase I study of N1N11diethylnorspermine in patients with advanced malignancy

  2004cited by this paper
• Phase I Study of N1-N11-Diethylnorspermine (DENSPM) Administered TID for 6 Days in Patients with Advanced Malignancies

  2004cited by this paper
• A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer.

  2003cited by this paper
• Induction of the PAOh1/SMO polyamine oxidase by polyamine analogues in human lung carcinoma cells

  2003cited by this paper
• Phase I study of N(1),N(11)-diethylnorspermine in patients with non-small cell lung cancer.

  2002cited by this paper
• Cloning and characterization of a human polyamine oxidase that is inducible by polyamine analogue exposure.

  2001cited by this paper
• Phase 1 study of N1-N11-diethylnorspermine (DENSPM) administered TID for 6 days in patients with advanced malignancies.

  2001cited by this paper
• Terminally alkylated polyamine analogues as chemotherapeutic agents.

  2001cited by this paper
• Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.

  1998cited by this paper
• The natural polyamine spermine functions directly as a free radical scavenger.

  1998cited by this paper

• Metabolic reprogramming in cancer: signaling pathways and therapeutic targets.

  2026cites this paper
• Arginine and colorectal cancer: Exploring arginine-related therapeutic strategies and novel insights into cancer immunotherapies.

  2025cites this paper
• Polyamine metabolism in cancer: drivers of immune evasion, ferroptosis and therapy resistance

  2025cites this paper
• Novel Insight into the Multiple Biological Characteristics of Polyamines in the Gut: From Structure to Function.

  2025cites this paper
• Polyamine metabolism and anti-tumor immunity

  2025cites this paper
• Synthesis and evaluation of a 68Ga-labeled spermine derivative for tumor PET imaging.

  2024cites this paper
• Polyamine Signal through HCC Microenvironment: A Key Regulator of Mitochondrial Preservation and Turnover in TAMs

  2024cites this paper
• The Polyamine Analogue Ivospemin Increases Chemotherapeutic Efficacy in Murine Ovarian Cancer

  2024cites this paper
• The Synergistic Benefit of Combination Strategies Targeting Tumor Cell Polyamine Homeostasis

  2024cites this paper
• Epigenetic drugs as new emerging therapeutics: What is the scale's orientation of application and challenges?

  2023cites this paper
• Polyamine-Based Nanostructures Share Polyamine Transport Mechanisms with Native Polyamines and Their Analogues: Significance for Polyamine-Targeted Therapy

  2022cites this paper
• Polyamines in cancer: integrating organismal metabolism and antitumour immunity

  2022cites this paper
• Expanded Potential of the Polyamine Analogue SBP-101 (Diethyl Dihydroxyhomospermine) as a Modulator of Polyamine Metabolism and Cancer Therapeutic

  2022cites this paper
• The Association between Spermidine/Spermine N1-Acetyltransferase (SSAT) and Human Malignancies

  2022cites this paper
• Metabolism and function of polyamines in cancer progression.

  2021cites this paper
• A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma

  2020cites this paper